Mineralys Soars 88% on ASI Breakthrough, Options Chain Ignites Volatility

Summary
• Mineralys Therapeutics (MLYS) surges 88.82% intraday to $29.23, hitting a 52-week high of $30.14
• Dual catalysts: Positive phase III/II trial results for Lorundrostat and AstraZeneca’s Baxdrostat success drive ASI sector optimism
• Options chain sees 258.33% price change in MLYS20250919C30 call, signaling high volatility

Mineralys Therapeutics has ignited a historic intraday rally, surging to a 52-week high of $30.14 amid groundbreaking clinical trial results for its hypertension drug candidate, Lorundrostat. The stock’s meteoric rise—driven by a domino effect from AstraZeneca’s Baxdrostat trial success—has triggered a frenzy in the ASI (aldosterone synthase inhibitor) space. With turnover exceeding 13.4 million shares and a dynamic PE of -11.19, the stock’s volatility underscores the sector’s high-stakes innovation race.

ASI Breakthrough Ignites Mineralys' Record Surge
Mineralys’ 86.37% intraday surge stems from dual catalysts: its own positive phase III/II trial results for Lorundrostat and AstraZeneca’s Baxdrostat trial success. The 50 mg dose of Lorundrostat demonstrated a 16.9 mmHg systolic blood pressure reduction in uncontrolled hypertension patients, outperforming placebo by 9.1 mmHg. AstraZeneca’s Baxdrostat, a competing ASI, also met primary endpoints in phase III trials, creating a domino effect as investors extrapolate cross-sector demand for ASI therapies. This confluence of data has redefined the hypertension treatment landscape, with Mineralys positioned as a key player in a $200B+ market.

Pharma Sector Splits as ASI Innovators Outperform
While the broader pharmaceutical sector remains mixed, Mineralys’ ASI-focused momentum contrasts with AstraZeneca’s -0.08% intraday decline. The divergence highlights niche innovation’s power to outperform even sector leaders. AstraZeneca’s Baxdrostat success validates the ASI class, but Mineralys’ proprietary Lorundrostat pipeline—targeting hypertension, chronic kidney disease, and sleep apnea—offers a broader therapeutic footprint. This differentiation has amplified MLYS’s volatility, as investors bet on its first-mover advantage in a rapidly evolving niche.

Options Playbook: Capitalizing on ASI Volatility
• MACD: 0.359 (bullish), Signal Line: 0.224, Histogram: 0.136 (divergence)
• RSI: 68.89 (neutral), Bollinger Bands: $12.42–$16.11 (oversold)
• 200D MA: $13.19 (far below current price)

Mineralys’ technicals scream short-term bullish momentum, with the 52-week high at $30.14 acting as a critical psychological barrier. The stock’s 31.33% turnover rate and 86.37% intraday gain suggest strong institutional participation. For options traders, the MLYS20250919C30 call (strike: $30, exp: 9/19) and MLYS20251017C30 call (strike: $30, exp: 10/17) stand out:

• MLYS20250919C30:
- IV: 107.42% (high volatility)
- Leverage: 13.56% (amplifies directional bets)
- Delta: 0.46 (moderate sensitivity)
- Theta: -0.101 (aggressive time decay)
- Gamma: 0.058 (price sensitivity to movement)
- Turnover: $222,201 (liquid)
- Payoff at 5% upside ($30.29): $0.29/share (13.56% leverage amplifies returns)
- Why it works: High IV and leverage make this ideal for a short-term breakout play.

• MLYS20251017C30:
- IV: 88.14% (moderate)
- Leverage: 9.55%
- Delta: 0.50 (balanced exposure)
- Theta: -0.049 (moderate decay)
- Gamma: 0.045 (responsive to price swings)
- Turnover: $2,787 (liquid)
- Payoff at 5% upside: $0.29/share (9.55% leverage)
- Why it works: Serves as a longer-dated hedge against volatility decay.

Action: Aggressive bulls may consider MLYS20250919C30 into a breakout above $30.14. Conservative traders should pair MLYS20251017C30 with a stop-loss below $25.00 to manage risk.

Backtest Mineralys Stock Performance

Act Now: ASI Wave Propels Mineralys to Inflection Point
Mineralys’ 86.37% intraday surge has positioned it at a critical juncture: a successful close above $30.14 (52-week high) could cement its status as the ASI sector’s breakout leader. Technicals favor continuation, with RSI at 68.89 and MACD divergence hinting at momentum. However, AstraZeneca’s -0.08% decline underscores sector-wide caution. Investors must watch the $30.14 level and AZN’s next moves—AstraZeneca’s Baxdrostat commercialization timeline could either validate or undermine MLYS’s ASI thesis. Act now: Buy MLYS20250919C30 for a 5-day breakout play or MLYS20251017C30 for a longer-term ASI bet. Sector leader Johnson & Johnson (JNJ) remains flat with a 0.59% intraday gain, highlighting MLYS’s niche-driven outperformance.